Loomis, Sayles & Company’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-345,813
| Closed | -$23.5M | – | 777 |
|
|
2019
Q3 | $23.5M | Sell |
345,813
-53,669
| -13% | -$3.69M | 0.05% | 180 |
|
|
2019
Q2 | $23.2M | Buy |
399,482
+19,583
| +5% | +$1.16M | 0.04% | 187 |
|
|
2019
Q1 | $26.6M | Sell |
379,899
-19,093
| -5% | -$1.42M | 0.05% | 155 |
|
|
2018
Q4 | $25.7M | Sell |
398,992
-85,169
| -18% | -$5.97M | 0.06% | 138 |
|
|
2018
Q3 | $34M | Sell |
484,161
-5,193
| -1% | -$304K | 0.07% | 137 |
|
|
2018
Q2 | $24.7M | Buy |
489,354
+3,077
| +0.6% | +$122K | 0.05% | 201 |
|
|
2018
Q1 | $15.2M | Sell |
486,277
-11,777
| -2% | -$391K | 0.03% | 317 |
|
|
2017
Q4 | $17M | Sell |
498,054
-151,946
| -23% | -$4.84M | 0.04% | 308 |
|
|
2017
Q3 | $20.9M | Buy |
650,000
+84,676
| +15% | +$2.67M | 0.05% | 268 |
|
|
2017
Q2 | $18.4M | Sell |
565,324
-19,191
| -3% | -$608K | 0.04% | 277 |
|
|
2017
Q1 | $18.4M | Buy |
584,515
+53,344
| +10% | +$1.58M | 0.05% | 271 |
|
|
2016
Q4 | $15.6M | Sell |
531,171
-26,599
| -5% | -$811K | 0.04% | 332 |
|
|
2016
Q3 | $16.1M | Sell |
557,770
-58,725
| -10% | -$1.64M | 0.04% | 323 |
|
|
2016
Q2 | $16M | Sell |
616,495
-14,885
| -2% | -$395K | 0.04% | 333 |
|
|
2016
Q1 | $15.6M | Buy |
+631,380
| New | +$17.3M | 0.04% | 342 |
|
Loomis, Sayles & Company's GHDX Position: Q4 2019 in Review
Loomis, Sayles & Company sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 345,813 shares — an estimated $23.5M sold.
Loomis, Sayles & Company first reported a position in GHDX in Q1 2016 and held it in 15 quarters. The position peaked at $34M in Q3 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Loomis, Sayles & Company reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Loomis, Sayles & Company sold 345,813 Genomic Health, Inc. shares in Q4 2019, an estimated $23.5M.
- Loomis, Sayles & Company first reported a position in Genomic Health, Inc. in Q1 2016 and held it in 15 quarters.
- Loomis, Sayles & Company's Genomic Health, Inc. position peaked at $34M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Loomis, Sayles & Company's 13F filing for Q4 2019, filed 14 Feb 2020.